Statistics from Altmetric.com
Commentary on Lund LH, Benson L, Dahlström U, et al. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 2012;308:2108–17.
Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for approximately half of all patients with HF in the community.1 The condition is associated with substantial morbidity and mortality, yet no medications have been proven to reduce mortality in these patients. Debate continues about HFpEF and HF with reduced ejection fraction (HFrEF) representing overlapping or distinct phenotypes within the HF spectrum.2 ,3 The benefit of renin-angiotensin system (RAS) antagonists including ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) is well established in reducing mortality and morbidity in HFrEF. Although RAS activation is implicated in the pathophysiology of HFpEF, …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.